NCT06350682

Brief Summary

The Resilient HIV Implementation Science with SGM Youths using Evidence (RISE) Clinical Research Center will use a Type 2 hybrid-effectiveness-implementation study to evaluate the effectiveness and implementation of HMP, a youth-tailored digital health platform. It is hypothesized that SGM youths in the HMP intervention group will demonstrate improved PrEP initiation and viral load suppression over 12 months compared to the delayed HMP group.

Trial Health

78
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,500

participants targeted

Target at P75+ for not_applicable hiv

Timeline
37mo left

Started Mar 2026

Typical duration for not_applicable hiv

Geographic Reach
2 countries

3 active sites

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress7%
Mar 2026Jun 2029

First Submitted

Initial submission to the registry

February 20, 2024

Completed
2 months until next milestone

First Posted

Study publicly available on registry

April 5, 2024

Completed
1.9 years until next milestone

Study Start

First participant enrolled

March 4, 2026

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2029

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2029

Last Updated

May 19, 2026

Status Verified

May 1, 2026

Enrollment Period

3.3 years

First QC Date

February 20, 2024

Last Update Submit

May 14, 2026

Conditions

Outcome Measures

Primary Outcomes (3)

  • PrEP initiation for HIV seronegative seropositive

    For those HIV seronegative, initiation of pre-exposure prophylaxis (PrEP) (Oral PrEP dispensed by pharmacy or Long-acting injectable defined as receiving first dose)

    24 months

  • Viral load suppression for HIV

    HIV seropositive viral load suppression at 12 months of taking ART (defined as HIV viral load of less than 1,000 copies/mL)

    24 months

  • RE-AIM

    Implementation Effectiveness on reach (characteristics of participants enrolled), Adoption (HMP physician and client interaction), Implementation (barriers and facilitators), Maintenance (HMP immediate access group at 21-24 months) and cost effectiveness of the HMP (incremental costs effectiveness ration and net monetary benefit)

    24 months

Secondary Outcomes (4)

  • HIV testing cascade

    12-24 months

  • PrEP continuum

    12-24 months

  • HIV care and treatment continuum

    12-24 months

  • Implementation effectiveness

    24 months

Study Arms (2)

HealthMPowerment (HMP) Delayed Access

NO INTERVENTION

Delayed access for 12 months to the HMP app, individuals will have access but it will be restricted

HealthMPowerment (HMP) Open Access

EXPERIMENTAL

Full access to the HMP app

Behavioral: HealthMPowerment (HMP)

Interventions

Participants will be provided access to the status neutral platform (HMP)mobile app for 12 months exposure period or a delayed access period. The HMP is developed specific to RISE and will be adapted based off feedback from each local site via stakeholders/YABs. The HMP will encompass a range of features including a robust content management system and back end administrative dashboard, multi media resources and information center, social support features such as connections to peers and providers, interactive activities and self assessments, and flexible medication and health trackers. In addition the app will support HIV/STI test kit ordering and results portal and a gamified reward system. With real time analytics to monitor user engagement and response with the DHI we can adapt the delivery of tailored content to fit emergent HIV prevention and care challenges.

HealthMPowerment (HMP) Open Access

Eligibility Criteria

Age15 Years - 24 Years
Sexmale(Gender-based eligibility)
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Male sex at birth
  • Age 15-24 years
  • Own an Android or iOS smartphone
  • Had receptive or insertive sex with another man in the past 12 months
  • Receiving care or prevention services at the CBSP-associated with the CRPS at the time of study.

You may not qualify if:

  • Less than 15 years old
  • Greater than 24 years old
  • Inability or cognitively impaired to provide consent
  • Does not own an Android or iOS smartphone.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Icarh/Ihvn

Abuja, Nigeria, Nigeria

Location

Centre for Population Health Initiative

Lagos, Nigeria, Nigeria

Location

CIHEB Zambia Limited

Lusaka, Zambia, Zambia

Location

Related Publications (2)

  • Brasileiro J, Muessig KE, Lascko T, Sam-Agudu NA, Rochelle A, Mansfield ME, Ehoche A, Adebajo S, Hightow-Weidman LB, Charurat ME, Shoyemi E, Claassen CW, Trapence G, Kimani J, Aghedo OG, Ayorinde O, Sambambi K, Ndalumbira G, Gichuki R, Lavoie MC. Adapting the HealthMpowerment (HMP) mobile application for youth living with or at risk of HIV in Africa using the ADAPT-ITT model. Implement Sci Commun. 2026 Apr 13. doi: 10.1186/s43058-026-00913-2. Online ahead of print.

  • Adebajo S, Lascko T, Lavoie MC, Ehoche A, Mutumba C, Aernan NS, Nganga N, Njoroge B, Chinseu PD, Gichuki R, Ayorinde O, Aghedo OG, Sambambi K, Ndalumbira G, Ngulube MC, Chama J, Shoyemi E, Trapence G, Kimani J, Claassen CW, Sam-Agudu NA, Hightow-Weidman L, Charurat M; RISE Study. Implementing youth advisory boards with sexual minority adolescents and young men: sharing experiences, challenges and opportunities from East, South, and West Africa. Trials. 2026 Mar 11;27(1):307. doi: 10.1186/s13063-026-09596-5.

MeSH Terms

Conditions

Acquired Immunodeficiency Syndrome

Condition Hierarchy (Ancestors)

HIV InfectionsBlood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesSlow Virus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

February 20, 2024

First Posted

April 5, 2024

Study Start

March 4, 2026

Primary Completion (Estimated)

June 30, 2029

Study Completion (Estimated)

June 30, 2029

Last Updated

May 19, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will not share

Locations